» Articles » PMID: 31844124

Collision Cross Sections Obtained with Ion Mobility Mass Spectrometry As New Descriptor to Predict Blood-brain Barrier Permeation by Drugs

Overview
Journal Sci Rep
Specialty Science
Date 2019 Dec 18
PMID 31844124
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Evaluating the ability of a drug to permeate the blood-brain barrier is not a trivial task due to the structural complexity of the central nervous system. Nevertheless, it is of immense importance to identify related properties of the drugs either to be able to produce a desired effect in the brain or to avoid unwanted side effects there. In the past, multiple methods have been used for that purpose. However, these are sometimes methodologically problematic and do not claim universal validity. Therefore, additional new methods for judging blood-brain barrier penetration by drugs are advantageous. Accordingly, within the scope of this study, we tried to introduce a new structure-derived parameter to predict the blood-brain barrier permeation of small molecules based on ion mobility mass spectrometry experiments - the collision cross section, as an illustration of the branching and the molecular volume of a molecule. In detail, we used ion mobility quadrupole time-of-flight mass spectrometric data of 46 pharmacologically active small-molecules as well as literature-derived permeability and lipophilicity data to set up our model. For the first time we were able to show a strong correlation between the brain penetration of pharmacologically active ingredients and their mass spectrometric collision cross sections.

Citing Articles

SMART: A data reporting standard for mass spectrometry imaging.

Xi Y, Sohn A, Joignant A, Cologna S, Prentice B, Muddiman D J Mass Spectrom. 2023; 58(2):e4904.

PMID: 36740651 PMC: 10078510. DOI: 10.1002/jms.4904.


Compound Identification Strategies in Mass Spectrometry-Based Metabolomics and Pharmacometabolomics.

Hissong R, Evans K, Evans C Handb Exp Pharmacol. 2022; 277:43-71.

PMID: 36409330 DOI: 10.1007/164_2022_617.


Large-Scale Evaluation of Collision Cross Sections to Investigate Blood-Brain Barrier Permeation of Drugs.

Guntner A, Bogl T, Mlynek F, Buchberger W Pharmaceutics. 2021; 13(12).

PMID: 34959422 PMC: 8703848. DOI: 10.3390/pharmaceutics13122141.


Towards Deep Neural Network Models for the Prediction of the Blood-Brain Barrier Permeability for Diverse Organic Compounds.

Radchenko E, Dyabina A, Palyulin V Molecules. 2020; 25(24).

PMID: 33322142 PMC: 7763607. DOI: 10.3390/molecules25245901.


Integrating ion mobility and imaging mass spectrometry for comprehensive analysis of biological tissues: A brief review and perspective.

Rivera E, Djambazova K, Neumann E, Caprioli R, Spraggins J J Mass Spectrom. 2020; 55(12):e4614.

PMID: 32955134 PMC: 8211109. DOI: 10.1002/jms.4614.


References
1.
Nault M, Milne B, Parlow J . Effects of the selective H1 and H2 histamine receptor antagonists loratadine and ranitidine on autonomic control of the heart. Anesthesiology. 2002; 96(2):336-41. DOI: 10.1097/00000542-200202000-00018. View

2.
Neuhaus O, Hartung H . Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother. 2007; 7(5):547-56. DOI: 10.1586/14737175.7.5.547. View

3.
Agon P, Goethals P, Van Haver D, Kaufman J . Permeability of the blood-brain barrier for atenolol studied by positron emission tomography. J Pharm Pharmacol. 1991; 43(8):597-600. DOI: 10.1111/j.2042-7158.1991.tb03545.x. View

4.
Gerebtzoff G, Seelig A . In silico prediction of blood-brain barrier permeation using the calculated molecular cross-sectional area as main parameter. J Chem Inf Model. 2006; 46(6):2638-50. DOI: 10.1021/ci0600814. View

5.
Vasovic V, Banic B, Jakovljevic V, Tomic Z, Milic-Djordjevic V . Effect of aminophylline on aspirin penetration into the central nervous system in rats. Eur J Drug Metab Pharmacokinet. 2008; 33(1):23-30. DOI: 10.1007/BF03191015. View